Sign In
Buy HRMY
$35.24
-0.620 (-1.73%)
At Close: Jul 31, 2026
Harmony Biosciences: Up 40% Since My Last Coverage, Waiting For Another Opportunity
03:42am, Wednesday, 14'th Dec 2022
Harmony has done very well in the few months since I last covered it. I was overly cautious then and did not buy what I see could have been a great investment.
Hot Biotech Stocks Rise Into Leadership; Pass Buy Points Or Build Bases
02:10pm, Friday, 25'th Nov 2022
Top biotech stocks surge within the IBD 50. Some pass buy points while others build bases.
Why Harmony Biosciences (HRMY) Stock Might be a Great Pick
10:32am, Wednesday, 23'rd Nov 2022
Harmony Biosciences (HRMY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2022 Earnings Call Transcript
03:15pm, Tuesday, 01'st Nov 2022
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY ) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET Company Participants Luis Sanay - Head-Investor Relations John Jacobs - President & Chief
Harmony Biosciences Holdings, Inc. (HRMY) Beats Q3 Earnings and Revenue Estimates
10:32am, Tuesday, 01'st Nov 2022
Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 850% and 3.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead f
IPO Stock Of The Week: Harmony Biosciences Outperforms In A Tough Market
01:01pm, Friday, 21'st Oct 2022
IPO Stock Of The Week Harmony Biosciences is holding up well during the stock market correction. The post IPO Stock Of The Week: Harmony Biosciences Outperforms In A Tough Market appeared first on Inv
HARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2022 FINANCIAL RESULTS ON NOVEMBER 1, 2022
08:05am, Tuesday, 18'th Oct 2022
PLYMOUTH MEETING, Pa. , Oct. 18, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ: HRMY), a pharmaceutical company dedicated to developing and commercializi
Harmony Biosciences: In Harmony
05:50am, Friday, 23'rd Sep 2022
Harmony Biosciences has seen a strong performance of its WAKIX drug since it went public in 2020. This run up made that shares have done quite alright, vastly outperforming most IPOs of the time.
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
03:26pm, Wednesday, 31'st Aug 2022
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
08:05am, Wednesday, 17'th Aug 2022
PLYMOUTH MEETING, Pa. , Aug. 17, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ: HRMY), a pharmaceutical company focused on delivering innovative therapie
6 Analysts Have This to Say About Harmony Biosciences
08:05pm, Wednesday, 03'rd Aug 2022 Benzinga
Harmony Biosciences (NASDAQ:HRMY) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
3
2
0
0
L
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022
02:38pm, Wednesday, 03'rd Aug 2022 Benzinga
Upgrades
Bernstein upgraded the previous rating for Cognex Corp (NASDAQ:CGNX) from Market Perform to Outperform. In the second quarter, Cognex showed an EPS of $0.41, compared to $0.43 from the year-
Harmony Biosciences Holdings, Inc. (HRMY) Q2 2022 Earnings Call Transcript
05:00pm, Tuesday, 02'nd Aug 2022 The Motley Fool
HRMY earnings call for the period ending June 30, 2022.
Harmony Biosciences Holdings, Inc. (HRMY) Surpasses Q2 Earnings and Revenue Estimates
12:45pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 42.50% and 7.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for
Harmony Biosciences Reports Second Quarter 2022 Financial Results and Business Updates
11:30am, Tuesday, 02'nd Aug 2022 GlobeNewswire Inc.
WAKIX® (pitolisant) Net Revenue of $107.0 Million for Second Quarter 2022 Increase of 45% vs. the Same Period in 2021
